ARTICLE | Company News

Genoptix, HistoRx sales and marketing update

November 22, 2010 8:00 AM UTC

Genoptix launched NexCourse BCa by AQUA technology in the U.S. The tests are for confirmatory estrogen receptor, progesterone receptor, and EGF receptor 2 ( HER2; ErbB2; neu) status prior to hormonal or antibody-based therapy or chemotherapy when initial results are inconclusive or negative. ...